EPO RECEPTOR LICENSE AGREEMENTEpo Receptor License Agreement • December 11th, 2006 • Affymax Inc • Pharmaceutical preparations • Delaware
THIS AGREEMENT, effective this 5 day of September, 1996, between GENETICS INSTITUTE, INC., a corporation of the State of Delaware, with its principle place of business at 87 CambridgePark Drive, Cambridge, Massachusetts, 02140, hereinafter referred to at "GI" and the licensee set out on the signature page below, hereinafter referred to as "LICENSEE",
LICENSE AGREEMENTLicense Agreement • December 11th, 2006 • Affymax Inc • Pharmaceutical preparations • California
This Non-Exclusive License Agreement (this "Agreement"), effective as of August 13, 2001 (the "Effective Date"), is entered into by and between XOMA Ireland Limited, a company with limited liability organized under the laws of the Republic of Ireland having offices at Shan- non Airport House, Shannon, County Clare, Ireland (with its Affiliates, "XOMA"), and Affymax, Inc., a Delaware corporation having offices at 4001 Miranda Avenue, Palo Alto, California, 94304, U.S.A. ("Affymax").
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • December 11th, 2006 • Affymax Inc • Pharmaceutical preparations • New York
LICENSE, MANUFACTURING AND SUPPLY AGREEMENTLicense, Manufacturing and Supply Agreement • December 11th, 2006 • Affymax Inc • Pharmaceutical preparations • California
COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • December 11th, 2006 • Affymax Inc • Pharmaceutical preparations • New York
This Collaboration And License Agreement (the "Agreement") is entered into on June 27, 2006 (the "Effective Date") between Affymax, Inc., a Delaware corporation, with its principal place of business at 4001 Miranda Avenue, Palo Alto, CA 94304, U.S.A. ("Affymax"), and Takeda Pharmaceutical Company Limited, a company incorporated under the laws of Japan, with a place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka, 540-8645, Japan ("Takeda"). Affymax and Takeda are sometimes referred to herein individually as a "Party" and collectively as the "Parties".
LICENSE AGREEMENT (THERAPEUTIC PRODUCTS)License Agreement • December 11th, 2006 • Affymax Inc • Pharmaceutical preparations • Massachusetts
THIS LICENSE AGREEMENT (this "Agreement"), effective as of June 28, 1996 (the "Effective Date"), is by and among DYAX CORP., a Delaware corporation, and PROTEIN ENGINEERING CORPORATION, a Massachusetts corporation and wholly-owned subsidiary of Dyax Corp., each having a principal place of business at 765 Concord Avenue, Cambridge, Massachusetts 02138 (collectively referred to herein as "Licensor"); and AFFYMAX TECHNOLOGIES, N.V. ("Licensee"), having a registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 ONN, England.
LICENSE AGREEMENT (THERAPEUTIC PRODUCTS)License Agreement • December 11th, 2006 • Affymax Inc • Pharmaceutical preparations • Massachusetts
THIS LICENSE AGREEMENT (this "Agreement"), dated July 25, 2001 is between DYAX CORP. ("Licensor"), a Delaware corporation, having a principal place of business at One Kendall Square, Bldg. 600, Suite 623, Cambridge, Massachusetts 02139 and AFFYMAX, INC. ("Licensee"), a Delaware corporation, having a principal place of business at 4001 Miranda Avenue, Palo Alto, CA 94304.
